20 likes | 87 Views
The Use of Cost-Effectiveness Information in Coverage Policy Decisions in the U.S. and the U.K. Stirling Bryan Ph.D. University of Birmingham, U.K. University of British Columbia, Canada. Britain Stirs Outcry by Weighing Benefits of Drugs Versus Price.
E N D
The Use of Cost-Effectiveness Information in Coverage Policy Decisions in the U.S. and the U.K. Stirling Bryan Ph.D. University of Birmingham, U.K. University of British Columbia, Canada
Britain Stirs Outcry by Weighing Benefits of Drugs Versus Price Millions of patients around the world have taken drugs introduced over the past decade to delay the worsening of Alzheimer's disease. … But this year, an arm of Britain's government health-care system, relying on some economists' number-crunching, said the benefit isn't worth the cost. It issued a preliminary ruling calling on doctors to stop prescribing the drugs. THE WALL STREET JOURNAL November 22, 2005; Page A1